Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Price to FCFE (P/FCFE)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The solvency profile exhibits two distinct phases: a period of relative deleveraging between April 2022 and April 2023, followed by a structural shift toward higher leverage beginning in July 2023. Since the end of 2023, solvency metrics have remained elevated and relatively stable, indicating a permanent change in the capital structure rather than a temporary fluctuation.
- Debt to Equity Ratio
- A downward trend was observed from April 2022 (0.44) to a low of 0.36 in April 2023. This was followed by a sharp increase, peaking at 0.81 by December 31, 2023. From 2024 through June 2026, the ratio stabilized within a range of 0.66 to 0.79, suggesting a sustained increase in the proportion of debt relative to shareholder equity.
- Debt to Capital Ratio
- The ratio initially declined from 0.31 in early 2022 to a minimum of 0.26 in April 2023. A significant upward adjustment occurred in July 2023, reaching a peak of 0.45 by year-end 2023. For the subsequent periods ending in June 2026, the ratio remained consistently between 0.40 and 0.44, reflecting a higher reliance on debt within the total capital base.
- Debt to Assets Ratio
- This metric remained stable at approximately 0.20 during the first year before dipping to 0.18 in early 2023. A rapid increase was recorded in July 2023, moving to 0.30 and peaking at 0.32 in December 2023. For the remainder of the analyzed period, the ratio demonstrated high stability, fluctuating narrowly between 0.30 and 0.31, indicating that debt levels have grown in proportion to total asset growth.
- Financial Leverage
- Financial leverage decreased from 2.23 in April 2022 to 1.94 in April 2023. A subsequent surge led to a peak of 2.54 in December 2023. From January 2024 through June 2026, the leverage ratio fluctuated between 2.25 and 2.47, corroborating the trend of increased financial risk and a more aggressive use of debt to finance assets.
Debt Ratios
Debt to Equity
| Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Short-term borrowings, including current portion of long-term debt | ||||||||||||||||||||||||
| Long-term debt, excluding current portion | ||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||
| Total Pfizer Inc. shareholders’ equity | ||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||
| Debt to equity1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Debt to equity = Total debt ÷ Total Pfizer Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial trajectory from April 2022 through June 2026 exhibits a significant shift in solvency positioning, characterized by a sharp increase in leverage during the third quarter of 2023 followed by a period of relative stabilization.
- Total Debt Trends
- A stable debt profile was maintained through early 2023, with balances fluctuating between 35.8 billion and 40.3 billion USD. A substantial increase occurred in July 2023, where total debt rose to 65.3 billion USD, eventually peaking at 71.9 billion USD by December 2023. Following this peak, a gradual deleveraging trend is observed, with the balance settling between 61.8 billion and 64.8 billion USD throughout 2024 and 2025, ending at 63.2 billion USD in June 2026.
- Shareholders' Equity Dynamics
- Equity demonstrated consistent growth in the first year of the analyzed period, rising from 82.4 billion USD in April 2022 to a peak of 101.0 billion USD in April 2023. Subsequently, equity values experienced fluctuations, moving within a range of approximately 85.2 billion to 96.9 billion USD. The equity base remained robust, though it did not expand at a rate proportional to the debt increase observed in mid-2023.
- Debt to Equity Ratio Analysis
- The debt to equity ratio transitioned from a low-leverage state, ranging from 0.36 to 0.46, to a moderate-leverage state. The most acute shift occurred between April 2023 and July 2023, where the ratio increased from 0.36 to 0.66. After reaching a maximum of 0.81 in December 2023, the ratio stabilized, oscillating between 0.66 and 0.79 for the remainder of the period. The consistent maintenance of the ratio below 1.0 indicates that total equity continues to exceed total debt, suggesting a balanced capital structure despite the increased reliance on borrowed funds compared to the 2022 baseline.
Debt to Capital
| Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Short-term borrowings, including current portion of long-term debt | ||||||||||||||||||||||||
| Long-term debt, excluding current portion | ||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||
| Total Pfizer Inc. shareholders’ equity | ||||||||||||||||||||||||
| Total capital | ||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||
| Debt to capital1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
An analysis of the solvency metrics reveals a significant structural shift in the capital composition starting in mid-2023. The company transitioned from a period of relatively low leverage and declining debt ratios to a higher, stabilized baseline of debt utilization.
- Debt Accumulation and Volatility
- Total debt remained relatively stable between April 2022 and April 2023, fluctuating within the 35 billion to 40 billion USD range. A sharp increase occurred in July 2023, where total debt rose to 65.34 billion USD, eventually peaking at 71.89 billion USD in December 2023. Following this peak, a gradual deleveraging trend is observed through June 2025, with debt levels decreasing to 61.80 billion USD, before stabilizing around 63.19 billion USD by June 2026.
- Capital Base Expansion
- Total capital exhibited a steady upward trajectory from 118.73 billion USD in April 2022 to 136.86 billion USD in April 2023. Similar to the debt trend, a substantial increase was recorded in July 2023, reaching 164.36 billion USD. Throughout the remainder of the period, the capital base remained largely range-bound between 148 billion and 162 billion USD, indicating that the increase in debt was the primary driver of capital expansion.
- Debt to Capital Ratio Trends
- The debt to capital ratio showed a downward trend during the first year, reaching a minimum of 0.26 in April 2023. This was followed by a rapid escalation to 0.40 in July 2023 and a peak of 0.45 in December 2023. From January 2024 through June 2026, the ratio entered a stabilization phase, fluctuating narrowly between 0.40 and 0.44. This represents a permanent upward shift in the company's leverage profile compared to the 2022 levels.
Debt to Assets
| Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Short-term borrowings, including current portion of long-term debt | ||||||||||||||||||||||||
| Long-term debt, excluding current portion | ||||||||||||||||||||||||
| Total debt | ||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||
| Debt to assets1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The solvency profile exhibits two distinct phases: a period of low leverage followed by a significant capital expansion and subsequent stabilization. From April 2022 through April 2023, a conservative capital structure was maintained. A sharp inflection point occurred in mid-2023, where a substantial increase in total debt shifted the organization to a higher baseline of leverage.
- Debt to Assets Ratio Evolution
- The ratio remained relatively stable between 0.18 and 0.21 throughout the first year of the observed period. A rapid escalation is noted in July 2023, when the ratio rose to 0.30, eventually peaking at 0.32 by December 31, 2023. From March 2024 through June 2026, the ratio demonstrates consistent stabilization, oscillating narrowly between 0.30 and 0.31.
- Total Debt Dynamics
- A dramatic increase in total debt is observed between April 2023 and July 2023, with obligations rising from 35,892 million US$ to 65,341 million US$. After reaching a peak of 71,888 million US$ in December 2023, a gradual deleveraging trend emerges, resulting in a reduction to 63,194 million US$ by June 2026.
- Asset Base Correlation
- Total assets followed a parallel upward trajectory during the 2023 expansion, peaking at 226,501 million US$ in December 2023. This increase in the asset base suggests that the additional debt was utilized for asset acquisition or capital investment. The subsequent moderate decline in total assets to 201,131 million US$ by June 2026 occurred in tandem with debt reduction, which served to keep the debt-to-assets ratio constant.
Financial Leverage
| Jun 28, 2026 | Mar 29, 2026 | Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||
| Total Pfizer Inc. shareholders’ equity | ||||||||||||||||||||||||
| Solvency Ratio | ||||||||||||||||||||||||
| Financial leverage1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Financial leverage = Total assets ÷ Total Pfizer Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
An analysis of the solvency data reveals a period of asset expansion followed by a gradual contraction, coupled with fluctuating levels of financial leverage over the observed period.
- Total Asset Trends
- Total assets exhibited a consistent growth trajectory from April 2022, rising from 183,841 million to a peak of 226,501 million in December 2023. Following this peak, a gradual downward trend is observed, with assets declining to 201,131 million by June 2026.
- Shareholders' Equity Performance
- Shareholders' equity grew from 82,424 million in April 2022 to a maximum of 100,970 million in April 2023. After this peak, equity levels entered a period of volatility, generally fluctuating between 85,000 million and 93,000 million, eventually closing at 85,190 million in June 2026.
- Financial Leverage Dynamics
- The financial leverage ratio underwent three distinct phases. Initially, leverage decreased from 2.23 in April 2022 to a period low of 1.94 in April 2023, indicating an increase in the proportion of equity relative to total assets. This was followed by a sharp increase, peaking at 2.54 in December 2023. From 2024 through June 2026, the ratio stabilized, oscillating within a range of 2.25 to 2.47.
- Solvency Insight
- The divergence between asset peaks (December 2023) and equity peaks (April 2023) contributed to the spike in financial leverage observed in late 2023. The stabilization of the leverage ratio above 2.30 in the final quarters suggests a sustained shift toward a higher reliance on external financing compared to the position held in early 2023.